TY  - JOUR
T1  - Antimicrobial use in European long-term care facilities: results from the third point of prevalence survey of healthcare-associated infections and antimicrobial use, 2016 to 2017
AU  - Ricchizzi, Enrico
AU  - Latour, Katrien
AU  - Kärki, Tommi
AU  - Buttazzi, Rossella
AU  - Jans, Béatrice
AU  - Moro, Maria Luisa
AU  - Nakitanda, Olivia Aya
AU  - Plachouras, Diamantis
AU  - Monnet, Dominique L.
AU  - Suetens, Carl
AU  - Kinross, Pete
AU  - the HALT Study Group
AU  - Schmidt, Nicole
AU  - Ruscher, Claudia
AB  - Antimicrobials are commonly prescribed and contribute to the development of antimicrobial resistance in long-term care facilities (LTCFs). In 2010, the European Centre for Disease Prevention and Control initiated point prevalence surveys (PPS) of healthcare-associated infections and antimicrobial use in European LTCFs, performed by external contractors as the Healthcare-Associated infections in Long-Term care facilities (HALT) projects. Here, we investigated prevalence and characteristics of antimicrobial use and antimicrobial stewardship indicators in European LTCFs in 2016–17. Twenty-four European Union/European Economic Area (EU/EEA) countries, the former Yugoslav Republic of Macedonia and Serbia participated in the third PPS in European LTCFs. Overall, 4.9% (95% confidence interval: 4.8–5.1) of LTCF residents in the EU/EEA participating countries received at least one antimicrobial. The most commonly reported Anatomical Therapeutic Chemical (ATC) groups were beta-lactam antibacterials/penicillins (J01C), other antibacterials (J01X) (e.g. glycopeptide antibacterials, polymyxins), quinolones (J01M), sulfonamides and trimethoprim (J01E), and other beta-lactams (J01D). Urinary tract infections and respiratory tract infections were the main indications for antimicrobial prescription. This PPS provides updated and detailed information on antimicrobial use in LTCFs across the EU/EEA that can be used to identify targets for future interventions, follow-up of these interventions and promote prudent use of antimicrobials in European LTCFs.
KW  - 610 Medizin und Gesundheit
PY  - 2018
LA  - eng
PB  - Robert Koch-Institut
JO  - Eurosurveillance
VL  - 23
IS  - 46
DO  - 10.2807/1560-7917
ER  -